Spondyloarthritis & psoriatic arthritis
Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment
Authors' conclusion
With treatment, SEC-NR patients have a more pronounced type 1 IFN signature than SEC-R patients, suggesting a mechanism contributing to this larger inflammatory burden.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA), PBMC collected before and 24 weeks after secukinumab treatment
- Participants
- 30 patients
- Comparison
- Secukinumab responders vs nonresponders
- Outcome
- Immune profiles (CD4+ subset frequency; gene expression of mature CD45RO+CD45RA-CD4+ T cells)
- Follow-up
- Before and 24 weeks after secukinumab
Methodological detailsflow cytometry, NanoString analysis
- Flow cytometry
- NanoString analysis
Main finding
As reported in the abstract
Immune profiles
- SEC-NR had increased frequency of IL-17A-producing RORγt+CD4+ T cells vs healthy controls before secukinumab
- P < 0.01
- SEC-NR had significant increase of CXCR3+ CD4+ T cells before secukinumab vs secukinumab responders (SEC-R)
- P < 0.01
Original publication
Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment. Arthritis Rheumatol. Published 10 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →